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Abstract 
We studied the effect of the potent dietary antioxidant lycopene on multiple points along 
the nuclear factor kappa B (NF-B) signaling pathway in prostate and breast cancer 
cells. Lycopene significantly inhibited prostate and breast cancer cell growth at 
physiologically relevant concentrations of ≥1.25 M. Similar concentrations also caused 
a 30-40% reduction in IB phosphorylation in the cells, as determined by western 
blotting. Furthermore, the same degree of inhibition by lycopene was observed for NF-
B transcriptional activity, as determined by reporter gene assay. Concomitant with this, 
immunofluorescence staining of lycopene-treated cells showed a significant suppression 
(≥25%) of TNF-induced NF-B p65 subunit nuclear translocation. Further probing of 
lycopene’s effects on upstream elements of the NF-B pathway showed a 25% inhibition 
of both activity of recombinant IKKβ kinase in a cell-free in vitro assay, as well as activity 
of IKKβ immunoprecipitated from MDA-MB-231 cells treated with lycopene. In 
conclusion, the anti-cancer properties of lycopene may occur through inhibition of the 
NF-B signaling pathway, beginning at the early stage of cytoplasmic IKK kinase activity, 
which then leads to reduced NF-B–responsive gene regulation. Furthermore, these 
effects in cancer cells were observed at concentrations of lycopene that are relevant and 
achievable in vivo.  
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Introduction 
Prostate and breast cancer are two of the most common cancers worldwide. Prostate 
cancer is the most common cancer in men in the UK whilst breast cancer is the second 
most common cancer worldwide [1]. Although age and genetic factors play key roles, 
many studies indicate that lifestyle and diet are also significant aspects involved in 
cancer risk [2]. While preventative measures for both cancers are not well known, 
increased tomato intake, as highlighted first by the Health Professionals Follow-Up 
Study (HPFS) and a few other studies, has been linked to a reduced risk of prostate 
cancer [3, 4]. This potential chemo-preventative effect of increased tomato intake has 
been attributed to their richness in the red pigment carotenoid lycopene [5-8]. An 
association between plasma levels of lycopene and reduced risk of aggressive prostate 
cancer was reported in the Physicians Health study, which showed a 25% reduction in 
overall prostate cancer with plasma lycopene concentrations of 388 ng/ml (0.72 μM) 
and 44% lower incidence of aggressive prostate cancer at plasma lycopene 
concentrations of 356 ng/ml (0.66 μM) [5]. Due to its lipophilic nature, lycopene 
accumulates in the prostate, adrenal gland, testes and liver [9], which could explain its 
particular connection to prostate cancer risk. However, those findings led to 
investigations in a number of other cancer types and diseases. Although no significant 
link between dietary lycopene intake and breast cancer has yet been made [6, 7], a 
number of studies have demonstrated its chemo-preventative effects in breast cancer 
cell cultures [8, 10-12].  
The putative chemo-preventative activity of lycopene may be attributed to it potent 
antioxidant properties, derived from an electron-rich conjugated polyene chain, making 
it the most effective single oxygen-quenching carotenoid. Thus, it is highly effective in 
deactivating electrophiles such as oxygen and free radicals, formed as cellular oxidative 
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by-products, and which can cause oxidative stress and damage to cellular components 
[13]. Several cell culture-based investigations as well as some in vivo studies have shown 
lycopene to reduce DNA, protein and lipid damage from oxidative injury [14, 15]. 
However, in the case of prostatic carcinoma cell lines, different studies have reported 
variable inhibitory efficacies of lycopene as regards cell proliferation [16-19]. One study 
found lycopene at 1 μM to be sufficient for reducing proliferation in LNCaP cells [16], 
whereas in another study using PC3, DU145 and LNCaP cells, lycopene reduced cell 
viability and growth only at high concentrations (20µM) which is too high to be 
realistically achievable in vivo [17]. Within the physiologically relevant concentration 
range, no effect of lycopene was observed on LNCaP cell proliferation [18], whilst in 
contrast, a decrease in DU145 cell growth was reported at particularly low 
concentrations (10 nM) [19].  
Therefore, there remains an uncertainty as to the actual efficacy of lycopene as an 
anticancer molecule at physiologically relevant concentrations. We recently showed that 
lycopene inhibited angiogenesis of endothelial cells at physiologically relevant 
concentrations [20]. In prostate cancer cells, we showed that lycopene at 1.15 µM 
inhibited motility of PC3 and DU145 cells by 40% and 58% respectively, as well as 
inhibiting cell adhesion at ≥1.25 µM [21].  
The redox-sensitive transcription factor nuclear factor-B (NF-B) controls the 
transcriptional activation of many fundamental genes that regulates cell proliferation, 
apoptosis, metastasis, angiogenesis, inflammation, cellular adhesion and cell invasion 
[22]. Consequently, aberrant signaling along the NF-B pathway is believed to mediate 
several major cellular processes that occur in carcinogenesis. Constitutive activation of 
the NF-B pathway has been reported in several cancer cell lines [22], including from 
prostate tumors [23]. Over-activity of the NF-B pathway has been reported during the 
  
5 
early developmental stages of prostate cancer [24, 25], whilst inhibition of the NF-B 
pathway was shown to reduce the malignant properties of PC3 cells [26]. Furthermore, 
constitutive activation of NF-B has been linked to tumor progression in hormone-
independent breast cancer cell lines such as MDA-MB-231 [27], and breast gland 
development and breast carcinogenesis have been linked with NF-B-induced cyclin D1 
expression [28, 29] and selective activation of Bcl-3 and NF-B subunits, p50 and p52 
[30]. Furthermore, mutations in NFKB1, IKK2, IκBα and IκBε have also been identified in 
breast cancer [31] as well as defective IκBα in solid breast tumours [32]. Therefore, 
therapeutic targeting the NF-B pathway may represent a potential and multifaceted 
approach to combating cancers.  
Several studies have shown the ability of a variety of antioxidant compounds to 
suppress NF-B signaling in reproductive cancers including ovarian [33], breast [34] 
and prostate [35] cancers. Likewise, lycopene has been shown to inhibit Ras-dependent 
activation of the NF-B pathway in prostate cancer cells, resulting in cell cycle inhibition 
and apoptosis [36]. In SK-Hep-1 cells, lycopene reduced the binding affinity of the NF-B 
transcription factor complex to MMP-9 gene promoter sequences [37]. Therefore, these 
clues warrant further mechanistic investigation into the effects of lycopene on the NF-B 
signaling pathway in cancer cells. Importantly, whether lycopene can exert these 
potential effects at physiologically attainable concentrations also requires clarification. 
In the present study, we have conducted such an investigation, examining the NF-B 
signaling pathway at multiple levels in both human prostate and breast cancer cells. 
Here, we report that lycopene at physiologically relevant concentrations inhibits NF-B 
signaling through direct inhibition of the upstream activating kinase IKK, thus linking 
with suppression of the pathway observed at multiple points further downstream.  
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Materials and methods 
Lycopene preparation 
Pre-filtered tetrahydrofuran (THF; Sigma-Aldrich, Poole, UK), stabilized with butylated 
hydroxytoluene (BHT) at 0.0025% (w/v) to avoid peroxide formation, was used for the 
preparation of lycopene stock solutions and aliquots of solution were stored in dark in 
amber vials at -80°C. Lycopene was a gift of DSM Nutritional Products, Basel, 
Switzerland. For each experiment, the concentration of stock solution of lycopene was 
checked using an extinction coefficient of 196145 M-1 cm-1 for a solution of lycopene in 
THF. Prior to treatment of cells, the stock solution was first diluted 1:10 in FBS (fetal 
bovine serum; Lonza, Slough, UK), which acts an effective delivery vehicle for the 
cellular uptake and stability of lycopene [38]. This was then further diluted in DMEM 
medium (Dulbecco’s Modified Eagle Medium with 4.5 g/L L-glucose and L-glutamine; 
(Life Technologies Gibco, Paisley, UK) to achieve the desired experimental 
concentrations (0.5-5 μM). THF/BHT was used as a solvent vehicle control, and was also 
prepared through further dilution in the same manner as lycopene. We found that 
replenishing lycopene on a daily basis, which was performed in one of our experiments 
(Figure 1b), did not alter the experimental outcomes significantly compared to when the 
replenishment step was omitted.  
 
Cell culture 
Two human cancer cell lines were used in this investigation; PC3 cell line and MDA-MB-
231 cell line. The PC3 cell line is androgen-independent, highly malignant, pro-
metastatic, and is an established human prostate cancer cell line that was initiated from 
a bone metastasis of a 62-year old Caucasian. The MDA-MB-231 cell line is also pro-
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metastatic, estrogen-receptor negative and initiated from a breast metastasis of a 51-
year old female Caucasian. Both cell lines were purchased from European Collection of 
Cell Cultures (ECACC) in 2013, and were authenticated in-house by short tandem repeat 
(STR) analysis as previously described [39]. Cells were maintained in culture in 
complete medium composed of DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin (Lonza). Cells were incubated at 37°C in a humidified 
atmosphere of 5% CO2 in air. Cells were seeded at 0.5x103 for MTS assays in 96-well 
plates. Cells were seeded at concentrations of 1x104 cells/ml and 3x103 cells/ml in 24-
well plates, for western blot and luciferase assay, respectively. Cells used for IP were 
plated in 100mm dishes and treated once 80-90% confluence was reached. A cocktail of 
phosphatase inhibitors (Sigma-Aldrich), calyculin A and Sodium orthovanadate was 
added to cell lysates for all downstream applications.  
 
MTS cell growth assay 
Cell survival/growth in the presence of lycopene (0.5-5 μM, 48 h) was measured using 
the colorimetric MTS assay method. MTS tetrazolium compound (CellTiter 96® Aqueous 
MTS reagent; Promega, Southampton, UK) was mixed with PMS (phenazine 
methosulfate; Sigma-Aldrich) to form MTS assay reagent. 20 μL MTS-PMS complex was 
added per well to the 96-well plates at the end of the incubation periods with test 
agents. The catalytic activity of viable cells results in formazan dye production, which is 
then quantified. Cells were incubated with the dye for 1h, followed by absorbance 
reading at 492nm on a spectrophotometer (BioTek, Potton, UK).  
 
Western blot 
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Cells were seeded into tissue culture multiwell plates, and on the following day, the 
growth medium was replaced with serum-free medium containing various 
concentrations of either lycopene (1.25-5 μM) or THF as vehicle control. The cells were 
incubated further for 20 h. Recombinant human TNFα (R&D Systems, Abingdon, UK) 
was added to cells at 40ng/ml 30 mins prior to lysis for use as a positive control inducer 
of the NF-B pathway. Cells were washed with ice-cold PBS and lysed in 75 μl/well lysis 
buffer (150 mM NaCl, 1% Triton X-100, 0.5% Sodium Deoxycholate, 0.1% SDS, 50 nM 
Tris pH 8.0) containing protease and phosphatase inhibitor cocktail (Sigma-Aldrich), 
Calyculin A and Sodium orthovanadate. Cell lysates were removed from the well and 
clarified by centrifugation at maximum speed in a microfuge for 10 min at 4°C. The 
soluble cell extracts were loaded and separated by 10% SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE), alongside a molecular weight marker sample spanning the 
10-250kDa range (PageRuler Plus pre-stained protein ladder; Thermo Scientific, 
Loughborough, UK). Separated proteins on the gels were transferred to an activated 
PVDF membrane (Immun-Blot®; Bio Rad, Hercules, CA) using a fast semi-dry protein 
transfer method (Pierce G2 Fast Blotter and 1-Step Transfer Buffer; Thermo Scientific). 
Membranes were first incubated in blocking buffer (TBS-Tween 20 wash buffer 
containing 3% BSA) for 1 h at room temperature, with the exception of blots probed for 
phosphorylated IBα (p-IBα), which were not blocked so as to avoid over-quenching of 
the signal. Membranes were incubated with primary antibody overnight at 4°C, 
following which they were washed 3 x 5 min in wash buffer, and then incubated with 
HRP-conjugated secondary antibody for 2h at room temperature. Primary antibodies 
that had been characterized and reported in previous studies were used at 
recommended dilutions as follows: rabbit anti-p-IB-α (Ser 32/36) (Cat. No. sc-101713, 
Santa Cruz Biotechnology, Heidelberg, Germany) [40], and anti-actin rabbit polyclonal 
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(Cat. No. A2066-.2ML) (Sigma-Aldrich) [41]. Secondary antibody was horseradish 
peroxidase (HRP)-conjugated swine anti-rabbit Ig (Product No. p021702-2, Dako, 
Glostrup, Denmark) [42]. After washing, the membrane was developed by incubation 
with an enhanced chemiluminescence reagent followed by imaging of the blot under a 
CCD camera imaging system (G:BOX Chemi XL1.4, Syngene, Cambridge, UK).  
 
Cell fixing and Immunofluorescence-staining 
MDA-MB-231 and PC3 cells were seeded onto coverslips placed in 6 well culture plates. 
Cells at ~60% confluence were serum-starved overnight, after which they were pre-
treated with lycopene (5 μM) or THF vehicle for 2 h. Cells were then stimulated with 
TNFα (40ng/ml) over a time-course of 1-5 h. Cells were fixed with 4% 
paraformaldehyde diluted in PBS and then permeabilized with 0.2% Triton X-100 
diluted in PBS; 2 x 5 min PBS washes were performed in between fixing and 
permeabilization. Cells were blocked for 1 h at room temperature with 10% horse 
serum diluted in PBS, followed by 1 x 5 min PBS wash. Cells on coverslips were 
incubated with rabbit polyclonal NF-B p65 primary antibody (C-20; Santa Cruz) [43] 
for 1 h at room temperature. The secondary antibody was Alexa Fluor 488-conjugated 
donkey anti-rabbit IgG (A-21206; Life Technologies) [44], incubated for 1 h at room 
temperature in the dark. Three x 5 min washes were performed between antibody 
incubation stages. Cells were mounted onto microscope slides using Vectashield (Vector 
Laboratories, Burlingame, CA). Images were obtained using a fluorescence microscope 
(FSX100; Olympus, Southend-on-Sea, UK).  
 
NF-B-responsive gene activation reporter assay 
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The NF-B activity level in cell lysates at the level of NF-B–responsive gene expression 
was measured by luciferase-based reporter assay (Promega dual-luciferase reporter 
assay system). The firefly luciferase reporter plasmid contains 5 copies of an NF-B 
response element (PGL4.32[luc2P/NF-B-RE/Hygro] vector; Promega). This plasmid 
drives transcription of the luciferase reporter gene luc2P (Photinus pyralis). Cell 
treatment incubation time for luciferase assay lysates was approximately 72 h and did 
not include a serum starvation period. Each concentration of lycopene (0.5-5 μM) had an 
equivalent dilution of THF as matched control. Cells were transfected 24 h after plating 
with firefly and transfection control Renilla luciferase reporter plasmids using 
jetPRIME transfection reagents according to manufacturer’s protocol (Polyplus, 
Nottingham, UK). Cells were incubated with transfection reagent mixed with firefly and 
transfection control Renilla luciferase reporter plasmids, and 72 h later were washed 
with PBS and lysed with luciferase assay lysis buffer (Promega). Luciferase levels were 
measured for 10 sec using a luminometer (1450 microbeta, PerkinElmer, Seer Green, 
UK). Background readings of untransfected control lysates were subtracted from 
luminescence values. Values were normalized against positive transfection control 
(Renilla luciferase).  
 
Immunoprecipitation 
Once cells reached 80-90% confluence in 100mm dishes, cells were treated accordingly, 
by incubation overnight with THF, lycopene and staurosporine (10nM) as an IKK 
inhibitor positive control. Cells were washed with ice-cold PBS and lysed with 1 ml 
Pierce IP lysis buffer (Thermo Scientific) per dish. Cell lysates were clarified by 
centrifugation and pre-cleared with 10ul protein A/G-agarose beads (Santa Cruz) 1 h at 
4°C with constant rotation. Lysates were then incubated with 2ug anti-IKKβ rabbit 
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polyclonal (Cat. No. SAB1300467-100UG) [45] 1 h on ice. Anti-Trx rabbit polyclonal 
antibody (Santa Cruz) was used as a negative control pulldown antibody. After this, 10ul 
protein A/G-agarose beads was added to each sample and incubated further for 1 h at 
4°C with constant rotation. Beads were pelleted by centrifugation at 8000 x g for 1 min 
and the supernatant removed. Beads were washed by suspension in ice-cold IP lysis 
buffer followed by centrifugation at 8000 x g for 1 min, repeated three times, discarding 
the supernatant each time.  
 
In vitro IB kinase (IKK) activity assay 
The IB kinase β (IKKβ) Kinase Enzyme System and ADP-Glo™ Kinase assay were 
performed according to the manufacturer’s instructions for each assay (Promega) in 96-
well plates. The beads pellet obtained from immunoprecipitation of IKKβ was washed a 
final time with IKK reaction buffer (8000 x g for 1 min), discarding the supernatant. The 
ADP-Glo™ Kinase assay reaction buffer, containing ATP (25 μM) and the IKKβ substrate 
peptide IKKtide (0.2 ug/ul) (Promega) were added directly to the pellet, and the kinase 
reaction incubated for 1 h at room temperature, to allow IKK to convert ATP to ADP. 
After this, the beads were centrifuged (8000 x g for 1 min) to separate them from the 
supernatant, to be used for western blot analysis (see above). Subsequent probing of the 
pulldowns with the anti-IKK antibody in western blot revealed that the IKK IPs from 
each sample were successful and even. The supernatant was added to a 96-well plate 
and ADP-Glo™ reagent (Promega) was added to the wells and incubated at room 
temperature for 40 min, to halt the kinase reaction and deplete any remaining ATP. 
Kinase detection reagent was then added to wells and left to incubate for a final 30 min 
at room temperature. This final step converts ADP to newly synthesized ATP via a 
luciferase reaction. The same assay was also performed in a cell-free system. 100ng 
  
12 
recombinant IKKβ (Sigma-Aldrich) was pre-incubated with lycopene (5 μM) and assay 
reagents for 1 h. The reaction was then induced and incubated with IKKtide for a further 
hour. Luminescence was read using a microplate reader (BMG Labtech Fluorstar 
Optima, Offenburg, Germany). 
 
Statistical analysis 
ImageJ software (http://imagej.nih.gov/ij/) was used to perform densitometric analysis 
of relative nuclear:cytoplasmic ratio of immunostained cells and western blot protein 
bands, and density values of bands of interest were normalized against those of bands 
for actin. Paired T-test was used for pairwise analysis of THF- and lycopene-treated cells 
at varying concentrations; a p value ≤0.05 was considered statistically significant. One 
way ANOVA with Tukey post hoc test was used for dose-response values. Prism software 
(GraphPad, La Jolla, CA) was used for all statistical analyses.  
 
 
Results 
Lycopene inhibits proliferation in PC3 and MBA-MD-231 cells 
We began our investigation by studying the effect of lycopene on the proliferation of 
prostate cancer cells. We found that incubation of PC3 and MBA-MD-231 cells for 48 h 
with lycopene (0.5-5 μM) caused a concentration-dependent decrease in growth of both 
cells lines, relative to THF vehicle (ANOVA, p < 0.05, DU145 (p < 0.0001) and PC3 (p < 
0.001) vs control from 1.25 μM concentration upwards (Figure 1a). We found that the 
growth inhibitory effect of lycopene was significant only after incubation with cells for 
48h. MBA-MD-231 cells that were treated with lycopene (5 μM) or THF for 24 h showed 
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no significant differences in growth, whereas 48 h incubation with lycopene resulted in 
an approximately 16% reduction versus THF (Paired T-test, p < 0.05) (Figure 1b).  
 
Lycopene inhibits IB phosphorylation in PC3 and MBA-MD-231 cells 
To determine whether lycopene has an effect on NF-B signaling pathway we initially 
investigated its effect on phosphorylation of inhibitor of kappa Bα (IBα). PC3 and MBA-
MD-231 cells were serum-starved and treated for 20 h with a range of concentrations of 
lycopene (1.25-5 μM), or THF solvent vehicle. We employed western blotting technique 
and found that in both cell lines a 30-40% reduction in p-IBα protein levels was 
observed in lycopene-treated cells relative to THF. This effect was significant at all 
concentrations tested (1.25-5 μM) (Figure 2a). Furthermore, lycopene also significantly 
inhibited p-IBα protein levels in both cancer cell lines pretreated for 30 min with TNFα 
in a concentration-dependent manner (Figure 2b; Suppl Fig. S1). Therefore, lycopene 
inhibited NF-κB signaling in prostate cancer cells at the level of IBα phosphorylation by 
IKK, under both basal and TNF-stimulated conditions (Paired T-test, *p < 0.05 vs THF). 
We initially included a third cell line (human epithelial prostate cell line PNT2), however 
p-IBα protein levels in this non-tumour cell line were too low to be detected (data not 
shown). 
 
Lycopene inhibits TNFα induced NF-κB p65 nuclear translocation in MDA-MB-231 and PC3 
cells 
We then tested if the inhibition of IBα phosphorylation by lycopene was concomitant 
with a decrease in NF-κB nuclear translocation. To determine this, we performed 
immunofluorescence-staining for the NF-κB p65 subunit (Figure 3). MDA-MB-231 and 
PC3 cells were serum starved overnight and then treated with lycopene (5 μM) or THF 
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vehicle the next day for 2 h. Following this, p65 nuclear translocation was induced in 
cells with TNFα (40ng/ml) over a time-course of 1-5 h. A peak effect by TNFα was found 
to occur at 2 h in both cell lines (MDA-MB-231, Figure 3a; PC3 Figure 3b) where the p65 
nuclear:cytoplasmic ratio was ~2.5x greater than basal levels. Lycopene significantly 
suppressed p65 nuclear translocation from 2-5 h by at least ~25%, which almost 
mirrored basal levels in the presence of THF vehicle and absence of TNFα stimulation. 
The most significant effect of lycopene in both cell lines also occurred at 2 h, where p65 
nuclear translocation was inhibited by approximately ~60% compared to cells in 
vehicle only (paired T-test, *p < 0.05 vs THF).  
 
Lycopene inhibits NF-κB transcriptional activity in MBA-MD-231 and PC3 cells 
We investigated whether the inhibition of p65 nuclear translocation caused by lycopene 
occurred at a transcriptional level downstream of the NF-κB pathway. For this we 
utilized a NF-B-responsive gene activation reporter assay. PC3 and MBA-MD-231 cells 
were treated with a range of concentrations of lycopene (0.5-5 μM) or THF solvent 
vehicle alone for 72 h. Incubation of prostate cancer cells with lycopene caused a 
concentration-dependent decrease in NF-κB transcriptional activity, with reductions of 
20-40% and 20-50% in MDA-MB-231 (p < 0.05) and PC3 cells (p < 0.001), respectively, 
in comparison to cells incubated with vehicle at the same dilutions (Figure 4). The 
inhibitory effects were significant starting from 1.25 μM (ANOVA, p < 0.05), with 0.5 μM 
lycopene showing no significant effect.  
 
Lycopene reduces IKKβ kinase activity in a cell-free system and in intact MBA-MD-231 cells 
Finally we examined whether lycopene’s inhibitory effect on the NF-κB pathway also 
occurred at an upstream level by studying its effect on IKKβ kinase activity. We tested 
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this in a cell-free system as well as using MBA-MD-231 cells. Pure recombinant IKKβ was 
pre-incubated with 5 μM lycopene or THF solvent for 1 h, then a further incubation for 1 
h in the presence of IKKtide substrate. Lycopene reduced IKKβ kinase activity by ~25% 
when compared to THF control (p < 0.01) (Figure 5a). Similarly, IKKβ from MBA-MD-
231 cells treated overnight (~15 h) with lycopene (5 μM) showed a reduction in activity 
by ~25% (Figure 5b) compared to THF-treated cells. A vehicle effect was observed in 
both cell-free system and in MBA-MD-231 cells; THF reduced IKKβ kinase activity by 
~20%. Staurosporine (10 nM) reduced IKKβ activity in cells by ~25% compared to 
baseline levels, and by ~40% in the presence of THF. This indicates that although there 
was a vehicle effect, this did not mask the effect of either lycopene or staurosporine. 
Therefore, these data indicate that lycopene directly acts to inhibit IKKβ kinase activity.  
 
 
Discussion 
In this study, we have investigated the effects of lycopene specifically on the NF-B 
signaling pathway. Here, we demonstrate that lycopene acts via inhibiting NF-B 
signaling, the influence of which have observed at multiple levels along the pathway. 
MTS proliferation assays showed that lycopene reduced proliferation in both PC3 and 
MBA-MD-231 prostate cancer cells, which was apparent only after 48 h incubation. The 
inhibition was concentration-dependent, including concentrations that are 
physiologically relevant (1.25-5 μM). A conceivable mechanism for this growth 
inhibition is through the induction of cell cycle arrest and apoptosis [14, 30, 46-48]. 
Several studies have previously reported lycopene to inhibit growth of prostate cells, 
including DU145, LNCaP and human prostate epithelial cells [14, 48, 49]. Additionally, 
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studies using MCF-7 breast cancer cell line have also noted anti-proliferative activity 
from lycopene [11, 50].  
We found that 20 h incubation with lycopene reduced phosphorylation of IκBα by 
approximately one third in both PC3 and MBA-MD-231 cells. This effect occurred both in 
the absence and presence of TNFα, a strong inducer of the NF-κB pathway [22]. The 
phosphorylation of IκBα occurs early in the NF-κB pathway; by which it instigates 
activation of this signal pathway, releasing NF-κB from sequestration by IκBα, and 
permitting translocation of NF-κB to the nucleus, hence driving target gene expression 
[22]. This therefore demonstrates that lycopene interferes with an early event in the NF-
B pathway, specifically the stage where IKK phosphorylates IκBα and thereby affects 
the cellular localization of NF-κB. The inhibition of IκBα phosphorylation occurred at all 
concentrations tested, including the lowest concentration (1.25 μM), which is an 
achievable physiological concentration of lycopene that has been measured in the blood 
[51, 52]. Furthermore, the maximum effect was observed at 2.5 μM; a higher 
concentration of 5 μM did not increase the effect. This effect was concomitant with 
lycopenes influence on nuclear translocation of NF-κB p65 subunit. We found that 
lycopene (5 μM) was able to dramatically inhibit TNFα-induced p65 nuclear 
translocation by as much as ~60% in MDA-MB-231 and PC3 cells. A similar effect has 
also been reported in LPS-stimulated murine dendritic cells, where lycopene (10 μM) 
was shown to suppress nuclear translocation of p65 [53]. 
We also probed the influence of lycopene on the downstream effects of the NF-B 
pathway, where we employed a luciferase reporter assay to determine the 
transcriptional activity of cells bearing an NF-B responsive promoter. In this 
experiment we uncovered that lycopene inhibited the NF-B pathway (~20-40%) in a 
concentration-dependent manner in both cell lines tested, which was consistent with 
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our findings for upstream IκBα phosphorylation. This effect was most evident from 
concentrations 1.25 μM and upwards.  
Finally we investigated the influence of lycopene on IKK, an upstream component of the 
activation of the NF-B pathway. The IKK enzyme complex phosphorylates IκBα in 
response to inflammatory stimuli such as TNFα and lipopolysaccharide (LPS) [54]. 
There is evidence for a correlation between inflammation and prostate cancer [55, 56] 
and that cytokine-induced activation of IKK (IκB kinase) is majorly involved in NF-B 
pathway activation [57-63]. Furthermore, there are also high levels of of IKK-i/IKKε and 
kinase activity in multiple breast cancer cell lines compared to MCF-10F breast 
epithelial cells [64], and increased IKKα and IKKβ activity in breast cancer cells and 
tumor specimens [65]. We employed an enzyme activity assay to observe the effects of 
lycopene on IKKβ activity. We found that lycopene (5 μM) significantly reduced IKKβ 
kinase activity by ~25% compared to vehicle in a cell-free system. This indicates a direct 
interaction between the IKKβ enzyme complex and lycopene. We then tested if a similar 
effect was achievable in whole prostate cancer cells. IKKβ obtained from MBA-MD-231 
cells treated with lycopene (5 μM) ~15 h showed reduced kinase activity by ~25% 
compared to cells treated with THF. Therefore, these data confirm that lycopene directly 
inhibits the activity of IKKβ and that this can also occur within prostate and breast 
cancer cells in vivo.  
While we have observed inhibition by lycopene of the NF-B pathway in prostate and 
breast cancer cells at different levels, our data indicate that lycopene acts at an early 
stage in the pathway. Lycopene inhibits phosphorylation of IκBα by reducing IKK 
activity in the cytoplasm. This then has the expected consequence of a reduced 
translocation of NF-B into the nucleus, and hence reduced NF-B–responsive gene 
regulation. Recently, one study has found that 1 h incubation with synthetic lycopene 
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derivatives reduces TNFα induced NF-B activity in T47D mammary carcinogenic cells 
and osteoblasts (MC3T3 and HOS) [60]. A preparation of intact lycopene (2.7 µM) with 
part-oxidised lycopene and derivatives resulted in 20-30% TNFα induced NF-B activity 
inhibition. Furthermore 1 h incubation with lycopene derivatives (~6-10 µM) resulted 
in attenuated p-IκB protein levels and IKKβ activity. However this study found that 
intact lycopene alone did not have any inhibitory effect.  
Our results showing lycopene suppression of the NF-B pathway are in keeping with the 
role of lycopene as a potent antioxidant alongside several other antioxidants that have 
also been shown to act as NF-B inhibitors, such as melatonin [33], grape seed extract 
[34] and nobiletin [35]. However, rather than through free radical scavenging, most of 
these antioxidants could possibly be acting in vivo through the ubiquitin proteasome 
system. Specifically, a target of lycopene could be the Keap1-Cul3-Rbx ligase complex, 
which ubiquitinates IKK and prepares it for degradation by the proteasome [66]. Under 
oxidative stress, or possibly through Keap1 mutations in certain cancers, Keap1 is 
modified and releases IKK, thus allowing it to phosphorylate IκB and activate the NF-B 
pathway. Therefore, in addition to targeting IKK activity, lycopene may be causing 
dysregulation of the Keap1-mediated IKK ubiquitination process, thereby preventing 
NF-B activation and subsequent tumor progression.  
It is also possible that antioxidants such as lycopene could be acting directly on the 
Keap1 complex. Keap1 is also a sensor of oxidative stress through its interaction with 
the major antioxidant gene regulator Nrf2 [66-68]. Under stress conditions, Nrf2, which 
is a transcription factor, is released from Keap1 and translocates to the nucleus, where it 
binds to the antioxidant response element (ARE) and stimulates expression of 
antioxidative gene products that protect the cell [66, 67]. Lycopene has previously been 
shown to activate Nrf2 [69] and therefore could be doing this via the Keap1 complex. In 
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addition, as the Keap1 complex appears to perform a pro-tumorigenic role through its 
concomitant activation of NF-B signaling and repression of Nrf2-ARE signaling, Keap1 
may represent an attractive therapeutic target in cancer [70]. Therefore, the targeting of 
Keap1 by lycopene confers an added advantage to lycopene beyond its recognised free 
radical scavenging functions.  
The results from our study indicate lycopene has an inhibitory effect on NF-B signaling 
at concentrations ≥1.25 μM. A lower concentration of 0.5 μM had no effect, which may 
explain why in previous studies lycopene failed to show significant protective effects in 
cancer patients at plasma lycopene concentrations of ~0.60 µM [61, 62]. Plasma levels of 
lycopene can be raised easily with the consumption of processed tomatoes to 1.2 µM 
[63, 71, 72], and with one paper reporting an increase of up to 2.1 μM [73]. One study 
looking at the effect of tomato paste on cultured PC3 cells and nude mice with PC3 
xenografts fed on a Western-like diet with 10% tomato paste for 6.5 weeks reported an 
inhibition of NF-κB activity, lycopene accumulation in the xenografts, and modulation of 
cancer and immune related genes [74]. Therefore, lycopene intervention studies of 
cancer patients should aim for raising the plasma lycopene levels above 1 µM and 
nutritionists should be looking into ways of increasing the bioavailability of lycopene 
from food/supplements so that plasma levels can be easily raised above 1.25µM. 
This study helps to expand our understanding of the chemo-preventative attributes of 
lycopene and provides further explanation of reduced risk of prostate cancer and 
decreased prostate and breast tumour aggression in those with higher dietary intake of 
tomato products. The putative properties of this compound provide grounds for future 
research into its clinical usefulness, as there are currently too few clinical investigations 
that have examined the effectiveness of lycopene in prostate cancer patients. Therefore 
this, and the fact that our study has shown effectiveness of lycopene at physiological 
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concentrations, warrants the need for further investigation in regards to its clinical 
efficacy. Furthermore, this study is the first to use prostate and breast cancer cells, as 
well as using physiological concentrations. 
In conclusion, we have shown in this study that lycopene inhibits the NF-B signaling 
pathway at multiple levels in human prostate and breast cancer cells in vitro. Therefore, 
our data indicate the possibility that physiologically relevant levels of plasma lycopene, 
achievable through diet supplementation, could act through suppression of the NF-B 
pathway in prostate and breast tumours in patients. Further, translational studies are 
required to determine this phenomenon in the clinical scenario.  
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Figure Legends 
 
Fig. 1. Effect of lycopene on survival/growth of PC3 and MDA-MB-231 cells. (A) 
Concentration-response experiment of effect of lycopene (0.5-5 μM) on PC3 and MDA-
MB-231 cells treated for 48 h, compared to THF vehicle. Viable cell number was 
measured via MTS assay as described. Values are mean±SEM normalized percentage 
viable cells for MDA-MB-231 cells (p < 0.0001 vs THF; n=4 experiments) and PC3 (p < 
0.001 vs THF; n=3 experiments). (B) Effect of lycopene (L) (5 μM) on MDA-MB-231 cells 
after 24 vs 48 h, compared to THF (T) vehicle. Viable cell number was measured via MTS 
assay as described. Values are mean±SEM of optical density (quadruplicate wells per 
treatment; 4 independent experiments). * p < 0.05; lycopene vs THF at 48 h.  
 
Fig. 2. Effect of lycopene on phosphorylation of IκBα (p-IκBα) in PC3 and MDA-MB-231 
cells. (A) Expression levels of p-IBα protein in serum-starved PC3 and MDA-MB-231 
cells treated with lycopene (1.25-5 μM) for 20 h compared THF vehicle. Band 
densitometric values for p-IκBα were normalized against band densities for actin. 
Values are expressed as percentage change from the control for that particular 
concentration. Values are mean±SEM of normalized densitometric value (n=4 separate 
experiments); *p < 0.05, **p < 0.01, ***p < 0.001 vs THF). (B) Effect of lycopene on 
TNFα–stimulated IκBα phosphorylation in PC3 and MDA-MB-231 cells. Serum-starved 
cells were pre-treated with lycopene (1.25-5 μM) (or THF vehicle) for 20 h, after which 
TNFα (40ng/ml) was added for 30 min prior to lysis. Band densitometric values for p-
IκBα were normalized against band densities for actin. Values are expressed as 
percentage change from the control for that particular concentration. Values are 
mean±SEM of normalized densitometric value (n=4 separate experiments); *p < 0.05, 
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**p < 0.01, ***p < 0.001 vs THF). (C) Western blot of p-IκBα protein level in lysates of 
serum-starved MDA-MB-231 cells treated with lycopene (L) at a range of concentrations 
(1.25-5 μM) or with THF vehicle (T) for 20 h, in the absence and presence of TNFα (40 
ng/ml; added 30 min prior to lysis). Bands show expression of p-IκBα (37 kDa; upper 
panel) and actin (42 kDa; lower panel). The blot has been cropped and is representative 
of 4 separate experiments performed, the analyzed data from which is presented in (A) 
and (B).  
 
Fig. 3. Effect of lycopene on TNFα induced NF-B p65 nuclear translocation in MDA-MB-
231 and PC3 cells. Serum-starved MDA-MB-231 (A) and PC3 (B) cells were pre-treated 
with lycopene (5 μM) or THF vehicle for 2 h, following which cells were stimulated with 
TNFα (40ng/ml) over a time-course of 1-5 h. (A; left panel) Representative p65 
immunofluorescence micrographs of MDA-MB-231 cells either untreated (Basal) or 
following 3h treatment with TNFα, with either THF or lycopene pre-treatment. No 
staining was visible when anti-p65 primary antibody was omitted. Scale bar represents 
15 μm. (A; right panel) Densitometric analysis from MDA-MB-231 fluorescence 
micrographs showing p65 nuclear:cytoplasmic ratio values as % change from basal. (B) 
Densitometric analysis from PC3 fluorescence micrographs. Results are the mean (±SD) 
of densitometric values from multiple cells (*p < 0.05, **p < 0.01), from a representative 
experiment.  
 
Fig. 4. Effect of lycopene on NF-B transcription factor activity in PC3 and MDA-MB-231 
cells. Cells were treated with lycopene (0.5-5 μM) or THF vehicle for 72 h, with each 
concentration of lycopene having an equivalent dilution of THF as matched control. 
Following this, cell lysates were subjected to luciferase assay, as described. Luciferase 
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activity is expressed as the ratio of NF-B-dependent firefly luciferase activity divided 
by transfection control (Renilla) luciferase activity. Values are given as percentage as 
normalized against THF control for each particular concentration. Results are the 
mean±SEM of luminescence from 3 separate experiments.  
 
Fig. 5. Effect of lycopene on kinase activity of IKKβ, in vitro as well as IKKβ derived from 
breast cancer cells. (A) Cell-free, in vitro kinase activity of recombinant IKKβ (100 ng) 
either alone or in the presence of lycopene (L) (5 μM) or THF vehicle (T). Values are 
normalized against IKKβ activity and expressed as a percentage of that activity. Results 
are the mean±SEM of luminescence values from 3 separate experiments (**p < 0.01 
lycopene vs THF treated cells). (B) The effect of lycopene (Lyc) (5 μM) on the activity of 
IKKβ obtained by immunoprecipitation from lysates of treated MDA-MB-231 cells, as 
compared to treatment with THF vehicle. Staurosporine (10 nM) (Stauro) acts to inhibit 
IKK as a positive control. Cells treated with both THF vehicle and 10 nM staurosporine 
(THF+Stauro) act as a control to determine if an effect still occurs in the presence of 
THF. IP control represents cell lysate immunoprecipitated with anti-Trx antibody as a 
negative control for the pulldown. Values are normalized against MDA-MB-231 baseline 
levels and expressed as a percentage. Results are the mean± SD of luminescence values 
from a representative experiment with triplicate readings of samples.  
 
 
